Form 4: Xeris Biopharma Holdings Director Dawn Halkuff Reports Stock Transactions

Director Dawn Halkuff reports acquisition of 50,000 shares of Xeris Biopharma Holdings common stock through a restricted stock unit award and disposition of 5,410 shares held indirectly through a revocable trust.

Summary

• On June 5, 2024, Dawn Halkuff, a director of Xeris Biopharma Holdings, Inc., reported transactions involving the company's common stock.
• Halkuff acquired 50,000 shares of common stock through a restricted stock unit (RSU) award under the company's 2018 Stock Option and Incentive Plan.
• The acquisition price for these shares was $0.
• These shares will vest in full on June 5, 2025, or the date of the company's next annual meeting of stockholders, whichever comes first.
• Halkuff also disposed of 5,410 shares held indirectly through the DAWN HALKUFF REVOCABLE TRUST U/A DTD 08/25/2017.
• Following these transactions, Halkuff directly owns 107,500 shares of Xeris Biopharma Holdings common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The acquisition of shares through RSU is a positive sign, but the disposition of shares from the trust is a slightly negative signal. Overall, the impact is balanced.

Positives

• The acquisition of 50,000 shares via RSU indicates confidence in the company's future performance.

Negatives

• The disposition of 5,410 shares from the revocable trust could be interpreted negatively, although the reason for the sale is not disclosed.

Risks

• The vesting of the RSU is contingent upon Halkuff's continued service until June 5, 2025, or the next annual meeting.
• The document does not provide any information about the company's overall financial health or future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge insider sentiment and potential future stock performance.

Stakeholder Impact

• Shareholders may view the acquisition of shares by a director as a positive signal.
• The disposition of shares from the trust may cause some concern among shareholders.

Key Dates